Shares of Apex Frozen Foods will get listed on the bourses today, 4 September 2017. The issue price is fixed at Rs 175 per share. The initial public offer (IPO) of Apex Frozen Foods received strong response from investors. The IPO was subscribed 6.14 times. The company had fixed the IPO price band at Rs 171 to Rs 175 per share. Apex Frozen Foods is one of the integrated producer and exporter of shelf stable quality aquaculture products.
L&T said its subsidiary L&T Infrastructure Development Projects (L&T IDPL) proposes to establish an infrastructure investment trust in the name of IndInfravit Trust under the provisions of the InvIT Regulations. In this regards, an application for registration of the InvIT as an infrastructure investment trust was filed by L&T IDPL with Securities and Exchange Board of India (SEBI) on 1 September 2017. The announcement was made on Saturday, 2 September 2017.
Coal India reported production and offtake figures for August 2017. Coal India said that production of the company and its subsidiary companies on provisional basis was 102% of targeted production at 37.63 million tonnes in August 2017. Offtake was 102% of target at 43.75 million tonnes in August 2017. The announcement was made after market hours on Friday, 1 September 2017.
Hero MotoCorp said its two-wheeler sales rose 10% to 6.78 lakh units in August 2017 over August 2016, riding on popular demand for its exciting range of two-wheelers. The high sales in August have ensued owning to the early arrival of the festival season this year. The company is poised to further consolidate its market leadership by meeting customer expectations with adequate inventory of its range of popular motorcycles and scooters at dealerships across the country. The announcement was made after market hours on Friday, 1 September 2017.
Shriram Transport Finance Company said that its NCD (non-convertible debentures) allotment committee allotted 500 NCDs aggregating to Rs 50 crore on private placement basis. The announcement was made after market hours on Friday, 1 September 2017.
Cadila Healthcare said it has received final approval from the United States Food and Drug Administration (USFDA) to market Mycophenalate Mofetil for Injection USP, 500 mg/vial. The drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants. The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The announcement was made on Saturday, 2 September 2017.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
